NCT04013217View on ClinicalTrials.gov

Evaluate Eribulin ORA in Subjects With Solid Tumors

PHASE1TerminatedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

July 29, 2019

Primary Completion Date

March 2, 2022

Study Completion Date

March 2, 2022

Conditions

Solid Tumor

Interventions

COMBINATION_PRODUCT

Eribulin ORA

Oral eribulin mesylate will be supplied as an aqueous solution and HM30181A-UK

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

Sponsors

Lead Sponsor

Health Hope Pharma

All Listed Sponsors

lead

Health Hope Pharma

INDUSTRY

NCT04013217 - Evaluate Eribulin ORA in Subjects With Solid Tumors | Biotech Hunter | Biotech Hunter